Thermo Fisher Collaborates with JW Therapeutics for CAR-T Therapies in China

 Thermo Fisher Collaborates with JW Therapeutics for CAR-T Therapies in China

Thermo Fisher Collaborates with JW Therapeutics for CAR-T Therapies in China

Shots:

  • The companies signed an agreement to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28
  • The focus of the agreement is to support clinical development & commercial manufacturing of leading CAR-T therapies in China including JW’s relmacabtagene autoleucel (relma-cel)
  • Relma-cel is an anti-CD19 CAR-T therapy for 3L treatment for r/r B-cell lymphoma and is expected to be first CAR-T therapy to be approved as a Category 1 biologics in China. Additionally, NMPA has accepted the NDA of Relma-cel

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: The Spruce

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post